Your browser doesn't support javascript.
loading
Follow-up strategies after trimodal treatment for muscle-invasive bladder cancer: a systematic review.
Kaufmann, Ernest; Aeppli, Stefanie; Arnold, Winfried; Balermpas, Panagiotis; Beyer, Jörg; Bieri, Uwe; Cathomas, Richard; de Bari, Berardino; Dressler, Marco; Engeler, Daniel S; Erdmann, Andreas; Gallina, Andrea; Gomez, Silvia; Guckenberger, Matthias; Herrmann, Thomas R W; Hermanns, Thomas; Ilaria, Lucca; John, Hubert; Kessler, Thomas M; Klein, Jan; Laouiti, Mohamed; Lauffer, David; Mattei, Agostino; Müntener, Michael; Nguyen, Daniel; Niederberger, Philipp; Papachristofilou, Alexandros; Prause, Lukas; Reinhardt, Karsten; Salati, Emanuela; Sèbe, Philippe; Shelan, Mohamed; Strebel, Räto; Templeton, Arnoud J; Vogl, Ursula; Wettstein, Marian S; Zihler, Deborah; Zilli, Thomas; Zwahlen, Daniel; Roth, Beat; Fankhauser, Christian.
Afiliación
  • Kaufmann E; Department of Urology, University of Lucerne, Luzerner Kantonsspital, Spitalstrasse, 6000, 16, Lucerne, Switzerland.
  • Aeppli S; Department of Oncology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
  • Arnold W; Department of Radiation-Oncology, Luzerner Kantonsspital, Lucerne, Switzerland.
  • Balermpas P; Department of Radiation-Oncology, Universitiy Hospital Zurich, Zurich, Switzerland.
  • Beyer J; Department of Oncology, Inselspital Bern, Berne, Switzerland.
  • Bieri U; Department of Urology, Kantonsspital Baden, Baden, Switzerland.
  • Cathomas R; Department of Urology, University Hospital Zurich, Zurich, Switzerland.
  • de Bari B; Department of Oncology, Kantonsspital Chur, Chur, Switzerland.
  • Dressler M; Department of Radiation-Oncology, Réseau Hospitalier Neuchâtelois, Neuchâtel, Switzerland.
  • Engeler DS; Zentrum Für Onkologie Luzern, Lucerne, Switzerland.
  • Erdmann A; Department of Urology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
  • Gallina A; Department of Oncology, Kantonsspital Baden, Baden, Switzerland.
  • Gomez S; Department of Urology, EOC Ente Ospedaliero Cantonale, Lugano, Switzerland.
  • Guckenberger M; Department of Radiation-Oncology, Kantonsspital Aarau, Aarau, Switzerland.
  • Herrmann TRW; Department of Radiation-Oncology, Universitiy Hospital Zurich, Zurich, Switzerland.
  • Hermanns T; Department of Urology, Spital Thurgau AG, Kantonsspital Frauenfeld, Frauenfeld, Switzerland.
  • Ilaria L; Division of Urology, Department of Surgical Sciences, Stellenbosch University, Western Cape, South Africa.
  • John H; Hannover Medical School, Hannover, Germany.
  • Kessler TM; Zentrum für Urologie Zürich, Zurich, Switzerland.
  • Klein J; Department of Urology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.
  • Laouiti M; Department of Urology, Kantonsspital Winterthur, Winterthur, Switzerland.
  • Lauffer D; Department of Neuro-Urology, Balgrist University Hospital, University of Zurich, Zurich, Switzerland.
  • Mattei A; Department of Urology, Kantonsspital Münsterlingen, Müsterlingen, Switzerland.
  • Müntener M; Department of Urology, Medical School, Ulm, Germany.
  • Nguyen D; Department of Radiation-Oncology, Hôpital Riviera Chablais, Rennaz, Switzerland.
  • Niederberger P; Department of Radiation-Oncology, University Hospital Geneva, Geneva, Switzerland.
  • Papachristofilou A; Department of Urology, University of Lucerne, Luzerner Kantonsspital, Spitalstrasse, 6000, 16, Lucerne, Switzerland.
  • Prause L; Department of Urology, Stadtspital Triemli, Zurich, Switzerland.
  • Reinhardt K; Department of Urology, Réseau Hospitalier Neuchâtelois, Neuchâtel, Switzerland.
  • Salati E; Department of Oncology, Luzerner Kantonsspital, Lucerne, Switzerland.
  • Sèbe P; Department of Radiation-Oncology, University Hospital Basel, Basel, Switzerland.
  • Shelan M; Department of Urology, Kantonsspital Aarau, Aarau, Switzerland.
  • Strebel R; Department of Urology, St. Clara Hospital Basel, Basel, Switzerland.
  • Templeton AJ; Department of Oncology, Hôpital Riviera Chablais, Rennaz, Switzerland.
  • Vogl U; Department of Urology, University Hospital Geneva, Geneva, Switzerland.
  • Wettstein MS; Department of Radiation-Oncology, Inselspital Bern, Berne, Switzerland.
  • Zihler D; Department of Urology, Kantonsspital Chur, Chur, Switzerland.
  • Zilli T; Department of Oncology, St. Claraspital Basel and Faculty of Medicine, University Basel, Basel, Switzerland.
  • Zwahlen D; Department of Oncology, EOC Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
  • Roth B; Department of Uro-Oncology, University of Toronto, Toronto, Canada.
  • Fankhauser C; Department of Oncology, Kantonsspital Aarau, Aarau, Switzerland.
World J Urol ; 42(1): 527, 2024 Sep 19.
Article en En | MEDLINE | ID: mdl-39297968
ABSTRACT

PURPOSE:

Optimal follow-up strategies following trimodal treatment for muscle invasive bladder cancer play a crucial role in detecting and managing relapse and side-effects. This article provides a comprehensive summary of the patterns and risk factors of relapse, functional outcomes, and follow-up protocols.

METHODS:

A systematic literature search on PubMed and review of current guidelines and institutional follow-up protocols after trimodal therapy were conducted.

RESULTS:

Out of 200 identified publications, 43 studies (28 retrospective, 15 prospective) were selected, encompassing 7447 patients (study sizes from 24 to 728 patients). Recurrence rates in the urinary bladder varied between 14-52%; 3-16% were muscle-invasive while 11-36% were non-muscle invasive. Nodal recurrence occurred at 13-16% and distant metastases at 15-35%. After 5 and 10 years of follow-up, around 60-85% and 45-75% of patients could preserve their bladder, respectively. Various prognostic risk factors associated with relapse and inferior survival were proposed, including higher disease stage (> c/pT2), presence of extensive/multifocal carcinoma in situ (CIS), hydronephrosis, multifocality, histological subtypes, incomplete transurethral resection of bladder tumor (TURBT) and incomplete response to radio-chemotherapy. The analyzed follow-up guidelines varied slightly in terms of the number, timing, and types of investigations, but overall, the recommendations were similar.

CONCLUSION:

Randomized prospective studies should focus on evaluating the impact of specific follow-up protocols on oncological and functional outcomes following trimodal treatment for muscle-invasive bladder cancer. It is crucial to evaluate personalized adaption of follow-up protocols based on established risk factors, as there is potential for improved patient outcomes and resource allocation.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria / Invasividad Neoplásica Límite: Humans Idioma: En Revista: World J Urol Año: 2024 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria / Invasividad Neoplásica Límite: Humans Idioma: En Revista: World J Urol Año: 2024 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Alemania